TriLink, QuantiBact Sign Distribution Deal | GenomeWeb

NEW YORK (GenomeWeb News) – TriLink BioTechnologies announced today a licensing deal with QuantiBact to offer twisted intercalating nucleic acid, or TINA, modified oligos.

TINA molecules are intercalators used to stabilize duplex formation, TriLink said, adding their properties improve the sensitivity and specificity of endpoint and real-time PCR. TriLink will makes TINA-modified oligonucleotides available starting next month.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.